Hemogenyx Pharmaceuticals Plc
HOPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $159 | $1,248 | $2,533 | $6,841 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $4 | $1 | $0 | $1 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $676 | $920 | $62 | $297 |
| Total Curr. Assets | $839 | $2,170 | $2,595 | $7,139 |
| Property Plant & Equip (Net) | $2,727 | $3,312 | $3,916 | $797 |
| Goodwill | $0 | $29 | $0 | $0 |
| Intangibles | $477 | $441 | $441 | $441 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $168 | $154 | $141 | $143 |
| Total NC Assets | $3,373 | $3,936 | $4,498 | $1,381 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $4,212 | $6,106 | $7,093 | $8,520 |
| Liabilities | – | – | – | – |
| Payables | $683 | $302 | $374 | $296 |
| Short-Term Debt | $954 | $273 | $322 | $10 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | -$478 | $77 | $52 | $47 |
| Total Curr. Liab. | $1,159 | $652 | $748 | $353 |
| LT Debt | $2,199 | $2,673 | $3,101 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $2,199 | $2,673 | $3,101 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $2,623 | $2,946 | $3,423 | $10 |
| Total Liabilities | $3,358 | $3,325 | $3,849 | $353 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $59 | $0 |
| Common Stock | $35 | $11,756 | $9,797 | $9,797 |
| Retained Earnings | -$29,424 | -$23,805 | -$17,114 | -$13,135 |
| AOCI | $8,898 | -$5,071 | -$59 | -$5,280 |
| Other Equity | $21,389 | $19,939 | $10,592 | $16,809 |
| Total Equity | $898 | $2,819 | $3,275 | $8,192 |
| Supplemental Information | – | – | – | – |
| Minority Interest | -$44 | -$38 | -$32 | -$24 |
| Total Liab. & Tot. Equity | $4,212 | $6,106 | $7,093 | $8,520 |
| Net Debt | $2,994 | $1,698 | $890 | -$6,831 |